Treatment Uterine Fibroid Size Chart and Fibroids: What to Know

Uterine fibroids (leiomyomas) are common, benign muscle tumors of the uterus. While many never cause problems, others can lead to heavy bleeding, pelvic pressure, pain, fertility challenges, or pregnancy complications. If you’ve been told you have fibroids, size is only one piece of the puzzle—but it does influence symptoms and which treatments are likely to work best. This guide explains how clinicians think about fibroid size, how it intersects with location and your goals, and what evidence-based treatments are available.

What are uterine fibroids?

Fibroids grow in or on the uterus and can be single or multiple. They are categorized by location:

• Submucosal: bulge into the uterine cavity (often linked to heavy bleeding and fertility issues)
• Intramural: grow within the muscular wall (can increase bleeding and pressure)
• Subserosal or pedunculated: grow on the outer surface (more often cause pressure or bulk symptoms)

By age 50, up to 70–80% of women may develop fibroids, though not all are symptomatic (sources: NIH/NICHD; ACOG).

Is there a standard fibroid size chart?

There is no single, universally accepted size chart for fibroids. Clinicians typically measure fibroids in centimeters (cm) by ultrasound or MRI and may also estimate overall uterine size in “weeks,” borrowing from pregnancy (for example, a “12-week-size” uterus is enlarged enough to reach just above the pubic bone). Size guides are used to communicate and plan treatment, not to label what is “normal.” Symptoms, location, number of fibroids, your age, and fertility goals are equally important (ACOG).

A practical fibroid size chart (approximate)

Use this as a general guide; your clinician’s measurements and recommendations may differ based on your anatomy and goals.

• Small: under 2 cm (about 0.8 inches); can be pea–cherry sized. Often monitored if no symptoms. Submucosal small fibroids may still cause heavy bleeding or infertility.
• Medium: 2–5 cm (about 0.8–2 inches); grape–plum sized. May cause heavier periods and some pressure.
• Large: 5–10 cm (about 2–4 inches); lime–orange sized. More likely to cause bulk symptoms (pelvic pressure, urinary frequency, constipation) and visible abdominal distension.
• Very large: over 10 cm (4 inches+); grapefruit sized or larger. Often associated with significant pressure and a uterus that may be described as “12–14 weeks” size or more.

Overall uterine size (rather than an individual fibroid) also matters. A uterus larger than 10–12 weeks’ size can influence which procedures are feasible and the surgical approach (ACOG).

How size and location influence symptoms

• Bleeding: Submucosal and intramural fibroids—especially those distorting the cavity—are strongly linked with heavy menstrual bleeding and anemia.
• Bulk/pressure: Larger intramural or subserosal fibroids may press on the bladder or bowel, causing urgency, frequency, constipation, back pain, or a “fullness” sensation.
• Fertility and pregnancy: Submucosal and some intramural fibroids can reduce implantation or increase miscarriage risk; large fibroids may increase certain pregnancy risks. Management is individualized (ACOG).

Treatment options, tailored by size, location, and goals

Evidence-based options range from watchful waiting to medications, uterus-sparing procedures, and surgery. Your preferences—especially around fertility and recovery time—are central to decision-making (ACOG; NIH).

Watchful waiting

• Who it suits: Small, asymptomatic fibroids; mild symptoms not affecting quality of life.
• What it involves: Periodic pelvic exams and imaging to monitor growth or new symptoms. Address iron deficiency if bleeding occurs.

Medications (symptom control and, sometimes, temporary shrinkage)

• NSAIDs: Help menstrual pain but less effective for heavy bleeding.
• Hormonal contraceptives: Pills, patch, ring can reduce bleeding. The levonorgestrel intrauterine system (LNG-IUD) significantly decreases bleeding, though expulsion risk is higher if the cavity is distorted (ACOG).
• Tranexamic acid: Non-hormonal option for heavy menstrual bleeding used during menses.
• GnRH agonists (e.g., leuprolide): Temporarily shrink fibroids and reduce bleeding; often used preoperatively or short-term due to menopausal symptoms and bone density loss (ACOG).
• Oral GnRH antagonists with add-back therapy: FDA-approved for heavy menstrual bleeding due to fibroids. Elagolix with estradiol/progestin (Oriahnn) and relugolix-estradiol-norethindrone (Myfembree) reduce bleeding and can shrink fibroids; use is time-limited due to bone effects and other risks. Discuss contraindications and monitoring with your clinician (sources: FDA Oriahnn; FDA Myfembree).

Note: Medications can control bleeding and sometimes reduce fibroid volume, but they generally don’t eliminate fibroids. Symptoms often return when therapy stops.

Uterus-sparing procedures

• Hysteroscopic myomectomy: Removes submucosal fibroids via the cervix; highly effective for heavy bleeding and fertility preservation when fibroids protrude into the cavity (ACOG).
• Uterine artery embolization (UAE): Blocks blood flow to fibroids, shrinking them and easing bleeding/pressure. Best for women not seeking pregnancy; some conceive afterward, but counseling on obstetric risks is important (ACOG; NIH).
• Radiofrequency ablation (laparoscopic or transcervical): Uses heat to shrink fibroids with small incisions or via the uterus; shorter recovery. Long-term fertility data are still evolving; recurrence can occur.
• MRI-guided focused ultrasound (MRgFUS): Noninvasive ultrasound waves ablate fibroid tissue under MRI guidance; suitable for selected patients and centers with expertise.

Surgery

• Myomectomy (laparoscopic, robotic, or open): Removes fibroids while preserving the uterus; preferred for those wishing to retain fertility. Recurrence occurs in about 15–30% within 5 years, depending on age, number, and size of fibroids (ACOG).
• Hysterectomy (vaginal, laparoscopic, or abdominal): Definitive cure for fibroid-related symptoms when childbearing is complete. Route depends on uterine size, anatomy, and prior surgery (ACOG).

How size guides treatment conversations

• Small (<2 cm): Monitor if asymptomatic; consider hormonal therapy, tranexamic acid, or hysteroscopic removal if submucosal and symptomatic.
• Medium (2–5 cm): Consider medications; hysteroscopy for submucosal lesions; myomectomy, radiofrequency ablation, UAE, or MRgFUS depending on location and goals.
• Large (5–10 cm): Procedures are often favored for durable relief. Myomectomy or UAE are common; preoperative GnRH therapy may reduce blood loss.
• Very large (>10 cm) or uterus >12–14 weeks size: Individualized surgical planning (often myomectomy or hysterectomy). Minimally invasive approaches may still be possible in experienced hands; counseling on risks and recovery is essential.

Fertility and pregnancy planning

If you are trying to conceive now or in the future, discuss:

• Which fibroids distort the cavity (submucosal/intramural) and whether removing them could improve fertility.
• Timing: Allow adequate healing time after myomectomy before attempting pregnancy (often several months; follow your surgeon’s guidance).
• Procedure choice: Myomectomy is typically preferred when fertility is a priority; UAE and MRgFUS are generally not first-line for those actively pursuing pregnancy (ACOG).

When to call a clinician

• Heavy bleeding soaking through pads/tampons hourly or passing large clots
• Symptoms of anemia: fatigue, shortness of breath, dizziness, chest pain
• Severe or sudden pelvic pain, fever, or fainting
• Rapid abdominal enlargement or new urinary or bowel symptoms

Building a plan you trust

Ask your clinician to review your imaging together and map each fibroid’s size and location to your symptoms and goals. Clarify which options are available locally, their recovery times, impact on fertility, potential need for repeat treatment, and insurance coverage. A second opinion with a fibroid specialist can be valuable for complex cases.

Trusted sources and further reading

• NIH/NICHD: Uterine Fibroids — condition overview and treatments: nichd.nih.gov
• ACOG Patient FAQ: Uterine Fibroids: acog.org
• FDA: Oriahnn (elagolix/estradiol/norethindrone) prescribing information: fda.gov
• FDA: Myfembree (relugolix/estradiol/norethindrone) prescribing information: fda.gov
• U.S. Office on Women’s Health: Uterine Fibroids: womenshealth.gov

This article is for education and doesn’t replace personalized medical advice. Work with your healthcare professional to choose the safest, most effective plan for you.

---

---